Barinthus Bio and Clywedog Therapeutics Announce Merger to Advance Diabetes and Celiac Disease Therapies
核心洞察
Barinthus Biotherapeutics and Clywedog Therapeutics (搜索) have entered into a definitive merger agreement to create a combined company focused on metabolic and autoimmune diseases, with the transaction expected to close in the first half of 2026.
The merged entity will advance three clinical-stage candidates targeting Type 1 diabetes (搜索), Type 2 diabetes (搜索), and celiac disease (搜索), with four key clinical data milestones anticipated within 18 months of closing.
The combined company will operate under the name Clywedog Therapeutics (搜索) and trade on NASDAQ under ticker "CLYD," with Clywedog shareholders owning approximately 66% and Barinthus Bio shareholders owning 34% of the merged entity.
Barinthus Biotherapeutics plc (NASDAQ: BRNS) and Clywedog Therapeutics (搜索) have announced a definitive merger agreement that will create a clinical-stage biopharmaceutical company focused on developing breakthrough therapies for metabolic and autoimmune diseases. The all-stock transaction, expected to close in the first half of 2026, will combine complementary expertise in immunology and metabolism to advance three clinical-stage candidates targeting diabetes and celiac disease (搜索).
The combined company will operate under the name Clywedog Therapeutics (搜索), Inc. and is expected to trade on NASDAQ under the ticker symbol "CLYD." Upon completion, Clywedog shareholders will own approximately 66% of the merged entity, while Barinthus Bio shareholders will hold 34%, based on the respective valuations at the time of the merger agreement execution.
Clinical Pipeline and Development Programs
The merged company's portfolio centers on three differentiated clinical-stage assets with potential for disease-modifying treatments across high-value indications.
CLY-101 (搜索) (Balomenib) represents a first-in-class menin (搜索) protein-protein interaction inhibitor designed to stimulate pancreatic islet regeneration. Through reversible inhibition, the compound enhances the production of glucose-regulating hormones, including insulin and glucagon, offering potential for both Type 1 and Type 2 diabetes (搜索) treatment. The therapy demonstrated safety and tolerability in a completed Phase 1 study in healthy volunteers, providing pharmacokinetic and pharmacodynamic data supporting its therapeutic potential.
Two Phase 2A proof-of-principle studies are planned for CLY-101 (搜索), with first topline data readouts expected in the second half of 2026 for both Type 2 diabetes (搜索) patients and Type 1 diabetes (搜索) Stage 3 patients. The compound's potential to work synergistically with GLP-1 agonists through increased GLP-1 receptor (搜索) expression positions it as a comprehensive approach to diabetes management.
CLY-201 (搜索) is a highly selective TYK2 (搜索) inhibitor targeting T-cell mediated inflammation that destroys insulin-secreting pancreatic beta cells, addressing an underlying cause of Type 1 diabetes (搜索). Phase 1 single and multiple ascending dose studies in healthy volunteers have been completed with no significant adverse events at exposure levels predicted to show efficacy. A Phase 2 study is planned for Type 1 diabetes Stage 2 patients to evaluate safety, glycemic control, and circulating C-peptide levels.
VTP-1000 utilizes Barinthus Bio's SNAP-Tolerance Immunotherapy platform as an antigen-specific tolerance immunotherapy for celiac disease (搜索) patients. The therapy is designed to prevent or reduce symptoms following gluten exposure. Five of six patients have been enrolled in the last cohort of the single ascending dose portion of the Phase 1 AVALON study, with the multiple ascending dose portion, including a gluten challenge, now initiated. Topline data from the single ascending dose portion is expected in Q4 2025, with multiple ascending dose results anticipated in mid-2026.
Strategic Rationale and Leadership
"We believe that the combination of Barinthus Bio and Clywedog will create immediate value and long-term upside for all stakeholders by diversifying our pipeline and increasing the number of meaningful clinical milestones," said Bill Enright, Chief Executive Officer of Barinthus Bio, who will serve as CEO of the combined company.
Dr. Iain Dukes, a venture partner at OrbiMed (搜索) who will serve as Executive Chairman of Clywedog Therapeutics (搜索), commented, "I am excited to be part of the combined company as we strive to develop potentially disease-modifying therapies for diabetes and autoimmune disorders."
The combined company's leadership team will include Bill Enright as CEO, Dr. Leon Hooftman as Chief Medical Officer, and Nick Fullenkamp as Vice President Corporate Development from Barinthus Bio, alongside Dr. Iain Dukes and Dr. Nikolay Savchuk from Clywedog's current leadership.
Drug Discovery Partnership and Support
ChemDiv (搜索), a global provider of integrated drug discovery solutions, announced it will continue providing chemistry, computational, and clinical pharmacology support to the combined entity. The collaboration includes accelerated CMC research, AI-enabled pharmacology, computational modeling, and translational biology services that were instrumental in advancing Clywedog's programs to the clinic in 2023-2024.
Roman Timakhov, Research Director at ChemDiv (搜索), stated: "We're proud to support the exceptional teams at Barinthus Bio and Clywedog. As they combine complementary strengths in immunology and metabolism, our integrated platform — AI-curated design, on-demand medicinal chemistry, and translational biology, pharmacology, and CMC — will continue transforming bold scientific hypotheses into differentiated drugs, faster."
Transaction Details and Timeline
Under the merger agreement terms, Barinthus Bio shareholders will receive one share of the combined company for each American Depositary Share or ordinary share owned, while Clywedog stockholders will receive 4.358932 shares for each common or preferred share owned. Prior to closing, the combined company may commence a partial tender offer to acquire shares for up to $27 million.
The transaction requires approval from both companies' stockholders and customary regulatory approvals. The combined company will be supported by existing cash and additional investments from OrbiMed (搜索) and Torrey Pines Investment LLC (搜索), both existing Clywedog shareholders, along with new investors. The estimated cash runway for the combined company extends through 2027.
Four key value-driving clinical milestones are expected within 18 months of the transaction closing, providing multiple opportunities for clinical proof of concept across the diabetes and celiac disease (搜索) programs. The merger brings together leading expertise in immunology and metabolic disease with the potential for synergistic combination therapies, particularly in Type 1 diabetes (搜索) where the companies' assets could work together to prevent inflammation and stimulate beta islet production.